Clinical trials
Leukemia clinical trials
Cancer of the blood and bone marrow that affects how blood cells are made. We’re tracking 1,284 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06544109Enrolling by invitationPhase 2/Phase 3
Venetoclax to prevent differentiation syndrome in APL
This trial tests adding venetoclax to standard treatment to prevent a serious side effect called differentiation syndrome in people with newly diagnosed acute promyelocytic leukemia (APL). Patients must be healthy enough to receive intensive chemotherapy.
Suzhou, JiangsuAges Any age - NCT06548230RecruitingPhase 1/Phase 2
Nadunolimab plus azacitidine for MDS and AML
This trial tests a new combination of drugs (nadunolimab plus azacitidine, sometimes with venetoclax) for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has not been treated much or has come back. The goal is to see if this combination can control the disease better.
Houston, TexasAges 18 years+ - NCT06532552RecruitingPhase 2
Comparing four drug combinations for older or unfit AML patients
This trial compares four different combinations of targeted therapy and chemotherapy for people with newly diagnosed AML who cannot have standard intensive chemo. The goal is to see which combination works best safely.
Suzhou, JiangsuAges 18 years+ - NCT06535113Recruiting
Inflammation and treatment response in AML
This study looks at how inflammation (the body's response to injury or infection) affects treatment outcomes in people with acute myeloid leukemia (AML). If you have a new diagnosis or have stored samples from a past diagnosis, you may help researchers understand why some people respond better to therapy.
Reggio Calabria, CalabriaAges 18 years+ - NCT06543381RecruitingPhase 1
Olutasidenib for IDH1-mutated blood cancers after transplant
This trial tests a drug called olutasidenib for people with certain blood cancers (AML, MDS, or CMML) that have a specific IDH1 gene change. The goal is to see if it can help prevent relapse after a donor stem cell transplant.
Duarte, CaliforniaAges 18 years+ - NCT06520098RecruitingPhase 2
BTK inhibitor with or without venetoclax for CLL/SLL
This trial tests whether adding venetoclax to your current BTK inhibitor (like ibrutinib, acalabrutinib, or zanubrutinib) works better than taking the BTK inhibitor alone. It's for veterans with CLL or SLL who have been on a BTK inhibitor for at least six months and have not had their disease get worse on that therapy.
San Francisco, CaliforniaAges 18–80 - NCT06516679RecruitingPhase 2
Customized treatment for infants with newly diagnosed leukemia
This trial tests a treatment plan that adjusts therapy based on each baby's risk level. It aims to improve outcomes for infants newly diagnosed with certain types of leukemia.
DaeguAges Up to 2 years - NCT06529731RecruitingPhase 2
Interferon-Gamma and Donor Cells for Relapsed Leukemia After Transplant
This trial tests combining a protein called interferon-gamma with an infusion of donor white blood cells to treat AML or MDS that returned after a stem cell transplant. The goal is to see if this combination helps the donor cells attack the cancer more effectively.
St Louis, MissouriAges 18 years+ - NCT06514768RecruitingEarly Phase 1
JY231 injection for B-cell acute lymphoblastic leukemia
This trial tests a new injection (JY231) for people with B-cell acute lymphoblastic leukemia (B-ALL) that has not responded well to treatment or has come back. It aims to see if the treatment can help reduce cancer cells in the bone marrow.
Kunming, YunnanAges Up to 75 years - NCT06514794RecruitingPhase 2
A study of a new cell therapy for T-cell acute lymphoblastic leukemia and lymphoma
This trial tests an investigational cell therapy that uses donated immune cells to find and destroy cancer cells in patients with T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) that has come back or not responded to treatment. The goal is to see if this therapy can help achieve remission for these patients.
Duarte, CaliforniaAges 6 months+ - NCT04385290RecruitingPhase 1/Phase 2
Testing midostaurin plus gemtuzumab for newly diagnosed AML
This trial studies whether combining two medicines—midostaurin and gemtuzumab (with standard chemotherapy)—can improve outcomes for newly diagnosed acute myeloid leukemia (AML). It is testing a first-line treatment plan tailored to specific genetic changes in the leukemia.
München, BavariaAges 18–75 - NCT06508775Recruiting
Long-term checkup for Miltenyi cell therapy patients
This study is a long-term check-in for people who received a special type of immunotherapy (CAR T cells) made by Miltenyi. It helps researchers see how you're doing over time after your treatment.
BerlinAges Any age - NCT06504459RecruitingPhase 2
Testing a drug combo for certain types of AML
This trial tests a combination of chemotherapy drugs (venetoclax, cladribine, cytarabine, and azacitidine) for people newly diagnosed with specific types of acute myeloid leukemia (AML) who cannot have or choose not to have standard intensive chemotherapy.
Miami, FloridaAges 18 years+ - NCT04150497RecruitingPhase 1/Phase 2
Testing a new cell therapy for CD22-positive leukemia
This trial tests UCART22, a new cell-based treatment, for people with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) that has the CD22 marker. It may help by attacking leukemia cells that carry CD22.
Los Angeles, CaliforniaAges 15–50 - NCT06481228Recruiting
TKI plus chemo and CAR-T for newly diagnosed Ph+ ALL
This trial tests combining a targeted drug (TKI) with chemotherapy and then CAR-T cells for adults who are newly diagnosed with Philadelphia chromosome-positive ALL. The goal is to see if this combination is safe and effective.
TianjinAges 18 years+ - NCT05305859RecruitingPhase 2
Venetoclax, chidamide, and azacitidine for hard-to-treat AML
This Phase 2 trial tests whether adding three medicines—venetoclax, chidamide, and azacitidine—can help adults whose AML has come back or did not respond to treatment. It may help shrink or control the leukemia and improve outcomes for people who fit the study’s health and lab requirements.
Xiamen, FujianAges 18 years+ - NCT06446661Recruiting
Text message reminders for ALL oral chemo
This study tests whether text message reminders can help patients stick to their daily oral chemotherapy schedule during the maintenance phase of ALL treatment. Participants receive friendly text reminders and can ask questions, aiming to make managing treatment easier.
Chicago, IllinoisAges 15 years+ - NCT06448013RecruitingPhase 1
Ziftomenib with chemo for pediatric AML
This trial tests a new drug, ziftomenib, combined with two standard chemotherapies (venetoclax and gemtuzumab) for children and young adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. It looks for specific genetic changes in the leukemia cells.
Houston, TexasAges 3–21 - NCT06439199Recruiting
Blood protein study in non-intensive chemotherapy for AML and MDS
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
Nantes, Loire-AtlantiqueAges 18–99 - NCT06440135RecruitingPhase 1
Ziftomenib maintenance after stem cell transplant for AML
This trial tests if the drug ziftomenib can help prevent AML from coming back after a stem cell transplant. It is for people who have certain gene changes (KMT2A rearrangement or NPM1 mutation) and are in remission or near-remission before transplant.
Boston, MassachusettsAges 18 years+ - NCT06428019RecruitingPhase 3
Comparing drug combinations for untreated CLL or SLL
This trial tests two different drug combinations (venetoclax with obinutuzumab or with acalabrutinib) to see how they affect the risk of tumor lysis syndrome in people with untreated CLL or SLL. It may help find the safest and most effective way to start treatment.
Tucson, ArizonaAges 18 years+ - NCT06408194RecruitingPhase 1
CD22 CAR T cells after Kymriah for B-cell cancers
This trial tests a new CAR T-cell therapy that targets CD22, after you've already received or been scheduled for a standard CD19-targeting CAR T-cell therapy (Kymriah). The goal is to see if giving a second type of CAR T cells can help when the first one doesn't work or the cancer returns.
Palo Alto, CaliforniaAges 1–25 - NCT01311258Recruiting
Tracking leftover cancer cells in AML or high-risk MDS
This study checks for “minimal residual disease,” meaning tiny numbers of leukemia cells that can remain after treatment. Results may help doctors better monitor your response and risk of relapse in AML or high-risk MDS.
Rochester, New YorkAges 18 years+ - NCT06389292RecruitingPhase 3
Study of Lisaftoclax plus azacitidine for new AML
This study tests a new pill (APG-2575, also called Lisaftoclax) combined with a standard injection (azacitidine) for adults with newly diagnosed AML who cannot take strong chemotherapy. The goal is to see if this combination works better than treatment alone.
Tianjin, Tianjin MunicipalityAges 18 years+
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia?
- Yes. Clin2 currently lists 1,284 recruiting leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.